MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 1 of 54    CPRC #2018LS066  
 
  
Masonic Cancer Center  
University of Minnesota  
Cancer Experimental Therapeutics Initiative (CETI)  and Bone Marrow Transplant Program  
 
 
A Multi -Center Phase 2 Study of Combined Modality Treatment with Ruxolitinib, 
Decitabine, and Donor Lymphocyte Infusion  for Post -Transplant Relapse  of AML or MDS  
 
MT201 8-07  
CPRC #20 18LS066  
IND# 18863  
 
 
University Of Minnesota  
Principal Investigator:  
Mark Juckett, MD  
 
Collaborator : 
Jeffrey S. Miller, M .D. 
 
Biostatistician:  
Ryan Shanley, MS  
 
Affiliate Institution s: 
Washington University, St. Louis, MO : 
Mark A. Schroeder, M.D., PI  
John F. DiPersio, M.D., Ph.D., Co -PI 
Jaebok Choi, Ph.D.*  
Matthew J. Christopher, M .D., Ph.D. 
 
*will not consent patients  
 
University of Rochester, Rochester, NY : 
Eric Huselton, M.D., PI  
 
 
Version Date:  
February 25, 2022  
Confidential  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 2 of 54    CPRC #2018LS066  
 
 Key Study Personnel Contact Information  
Site Contact Information  Role  
Masonic Cancer 
Center, University of 
Minnesota  Mark Juckett, MD  
Division of Hematology/Oncology/Transplantation  
Masonic Cancer Center  
University of Minnesota  
420 Delaware Street SE MMC 480  
Minneapolis, MN 55455  
Phone: 612 -624-6104  
Email: juck0001@umn.edu  IND 
sponsor/ 
Study PI  
Affiliate Manager  
Clinical Trials Office  
MMC 498  
420 Delaware Street SE  
Minneapolis, MN 55455  
Phone: 612 626 -5174  
Email:  affiliates@umn.edu  
Fax: 612 625 -6145  Affiliate 
Sites 
Manager  
Washington 
University  Mark Schroeder, M .D. 
Assistant Professor of Medicine, Division of Oncology, 
Section of Bone Marrow Transplantation and Leukemia  
Division of Oncology  
Washington University Medical School  
660 South Euclid Avenue  
Campus Box 8007  
Saint Louis, MO 63110  
314-454-8323 (office)  
314-454-7551 (fax)  
markschroeder@wustl.edu  Site PI  
University of 
Rochester  Eric Huselton, M.D.  
Wilmot Cancer Center  
University of Rochester Medical Center  
601 Elmwood Ave.  
Rochester, NY 14642  Site PI  
 
Refer to the Procedures Manual for Affiliate Sites for a complete list of st udy personnel and contact 
information.  
  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 3 of 54    CPRC #2018LS066  
 
 Revision History  
 
 
Revision 
# Version 
Date  Detail of Changes  Consent 
change  
 12/03/2018  Original to CPRC   
 1/16/2019  Updated study committee  
Section 15 : Statistical clarifications and m inor edits (error 
corrections and clarifications)  per UMN and University of 
Rochester CPRC stipulations  
Section 11. 2: Added optional research bone marrow biopsy  prior 
to cycle one  
Section 12.5 : Clarified institutional SAE reporting table based on 
current MCC SOPs   
1 03/18/2019  Title Page : Added IND #  
Per FDA request – Section 5.2 : Eligibility - Patients with Active 
GVHD will be excluded from the study  
Per FDA request - Section 15 .4 Stopping Rules and section 12.3,  
Event Reporting – the FDA will be notified if stopping rule is 
triggered  No 
2 03/27/2019  Clarifications to Section 11 : after clinical care planning meeting  
and IRB initial review : 
• Updated timing of windows around clinical care evaluations and 
research samples  
• Added recipient type and screening to clinical care evaluations  
• Clarified bone marrow biopsy timing  
• Removed specification  of sample tube color  
Section 12.3 , Section 12.4 , and Section 12.5  Updated sponsor 
reporting criteria  
Corrected typographica l errors  Yes 
3 05/01/2019  Administrative change:  
Section 11.1 and Section  11.2  Clarified standard of care and 
research bone marrow in order to synchronize timing.  No 
3A 09/03/2019  Administrative change:  
Section 11.1 and Section 11.2   Reorganized  calendar s for clarity  No 
4 11/25/2019  Administrative Changes:  
• Section 5.1 : Clarified that minors will either assent or be given 
an information sheet, per institutional IRB requirements  
• Removed eligibility checklists – these documents will now be 
stored in Oncore  
• Correction of typ ographical errors  Yes 
4A 01/03/2020  Section 8.5  removed karno fsky from re -screening procedures  No 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 4 of 54    CPRC #2018LS066  
 
 Revision 
# Version 
Date  Detail of Changes  Consent 
change  
5 09/18/2020  Synopsis , Section 5.1  Clarifications to Inclusion criteria  
Section 6 , Section 11.3  Clarified that related / unrelated donors 
will be screened and consented per individual institutional and/or 
NMDP SOPs  
Section 8.8  – Clarified that patients discontinuing DLI treatments, 
may continue to receive Ruxolitinib  
Section 11.1  Clarified timing of clinical screening labs  
Section 11.2  Removed screening research labs  
Section 12.3 , Section 13.3  and Section 13.5  Minor clarification to 
institutional monitoring  Yes; also 
removed 
study 
specific 
donor 
consents  
6 12/30/2020  Section 11.1  and Section 11.2  Clarifications to timing of procedures  
Section 12.2  and Section 15.4  Clarification to timing period of AE 
documentation  and stopping rules  No 
7 06/23/2021  Section 9.1  updated expected adverse events based on new 
Ruxolitinib IB  
Section 8.8  Minor edit to Duration of Study. Rationale clarification 
and consistency  Yes 
8 02/25/2022  Updated study PI and biostatistician  Yes 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 5 of 54    CPRC #2018LS066  
 
 Table of Contents  
Key Study Personnel Contact Information  .............................................................................................................  2 
Revision History  ......................................................................................................................................................  3 
Table of Contents  ...................................................................................................................................................  5 
Abbreviations  .........................................................................................................................................................  7 
Synopsis  ..................................................................................................................................................................  9 
Schema  ................................................................................................................................................................ . 12 
1 Objectives  ....................................................................................................................................................  13 
1.1 Primary Objective ................................................................................................................................  13 
1.2 Secondary Objectives  ..........................................................................................................................  13 
1.3 Corr elative Objectives  .........................................................................................................................  13 
2 Background  ..................................................................................................................................................  13 
2.1 DLI .......................................................................................................................................................  13 
2.2 HMAs  ...................................................................................................................................................  14 
3 Study Rationale  ............................................................................................................................................  14 
4 Study Design  ................................................................................................................................................  15 
5 Patient Selection  ..........................................................................................................................................  16 
5.1 Inclusion Criteria:  ................................................................................................................................  16 
5.2 Exclusion Criteria:  ...............................................................................................................................  18 
6 Donors  .........................................................................................................................................................  19 
7 Study Registration  ........................................................................................................................................  19 
7.1 Registration with the University of Minnesota Clinical Trial s Office  ...................................................  19 
7.2 Patients Who Do Not Begin Study Treatment  ....................................................................................  20 
8 Treatment Plan  ............................................................................................................................................  21 
8.1 Chemotherapy  Regimen  .....................................................................................................................  23 
8.2 DLI .......................................................................................................................................................  23 
8.3 Monitoring  ..........................................................................................................................................  24 
8.4 Ruxolitinib Do se modification  .............................................................................................................  24 
8.5 Re-screening Eligibility for Cycles 2 - 4 ................................................................................................ . 24 
8.6 Supportive Care  ..................................................................................................................................  26 
8.7 General Co ncomitant Medication Guidelines  .....................................................................................  26 
8.8 Duration of Study Treatment  ..............................................................................................................  26 
8.9 Duration of Study Participation  ..........................................................................................................  27 
9 Expected Adverse Events and Potential Risks  .............................................................................................  27 
9.1 Ruxolitinib  ...........................................................................................................................................  27 
9.2 Decitabine  ...........................................................................................................................................  28 
9.3 Risks Due to D LI ...................................................................................................................................  29 
10 Study Agent Information  .............................................................................................................................  30 
10.1 Ruxolitinib  ...........................................................................................................................................  30 
10.2 Decitabine  ...........................................................................................................................................  31 
11 Clinical Evaluations and Procedures  ............................................................................................................  33 
11.1 Required Clinical Care Evaluations  ......................................................................................................  34 
11.2 Patient – Research Related  .................................................................................................................  36 
11.3 Donor – Recommended Standard of Care  ..........................................................................................  37 
12 Adverse Event Monitoring, Documentation, and Reporting  .......................................................................  37 
12.1 Adverse Event Terminology  ................................................................................................................  37 
12.2 AE Documentation  ..............................................................................................................................  39 
12.3 SAE Documentation and MCC Reporting Requirements  ....................................................................  40 
12.4 Early Stopping Rule Events Documentation and Reporting Requirements  ........................................  41 
12.5 Institutional Event Reporting Table  ....................................................................................................  41 
13 Study Data Collection and Monitoring  ........................................................................................................  42 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 6 of 54    CPRC #2018LS066  
 
 13.1 Data Management  ..............................................................................................................................  42 
13.2 Case Report Forms  ..............................................................................................................................  43 
13.3 Data and Safety Monitoring Plan (DSMP)  ...........................................................................................  43 
13.4 Teleconferences – Lead Site and Affiliate Site  ....................................................................................  44 
13.5 Affiliate Site Monitoring  ......................................................................................................................  44 
13.6 Record Retention  ................................................................................................................................  44 
14 Study End points  ...........................................................................................................................................  45 
14.1 Primary Endpoint  ................................................................................................................................  45 
14.2 Secondary Endpoints  ..........................................................................................................................  45 
14.3 Correlative Endpoints ..........................................................................................................................  45 
15 Statistical Considerations  .............................................................................................................................  45 
15.1 Objectives and Study Design  ...............................................................................................................  45 
15.2 Statistical Analysis  ...............................................................................................................................  45 
15.3 Sample Size  .........................................................................................................................................  46 
15.4 Stopping Rules  ....................................................................................................................................  47 
16 Ethical and  Regulatory Considerations  ........................................................................................................  47 
16.1 Good Clinical Practice  .........................................................................................................................  47 
16.2 Ethical Considerations  .........................................................................................................................  47 
16.3 Informed Consent  ...............................................................................................................................  48 
17 References  ...................................................................................................................................................  49 
Appendix I – Karnofsky Performance Status Scale  ...............................................................................................  51 
Appendix II –– GVHD Grading Scales  ....................................................................................................................  52 
 
  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 7 of 54    CPRC #2018LS066  
 
 Abbreviations  
ABBREVIATION  DEFINITION  
ABO  TYPE A, TYPE B, TYPE O, OR TYPE AB 
AE  ADVERSE EVENT  
aGVHD  ACUTE GRAFT VERSUS HOST DISEASE  
AHC  ACADEMIC HEALTH CENTER  
ALT ALANINE AMINOTRANSFE RASE  
AML  ACUTE MYELO ID LEUKEMIA  
AST ASPARTATE AMINOTRANS FERASE  
BMP BASIC METABOLIC PANE L 
BMT BONE MARROW TRANSPLA NT 
CBC COMPLETE BLOOD COUNT  
CETI  CANCER EXPERIMENTAL THERAPEUTICS INITIATIVE  
CFR CODE OF FEDERAL REGULATIONS  
CMP  COMPREHENSIVE METABOLIC PROFILE  
CPRC  CANCER PROTOCOL REVIEW COMMITTEE  
CMV  CYTOMEGALOVIRUS  
CNS CENTRAL NERVOUS SYST EM 
CR COMPLETE REMISSION  
CRCL  CREATININE CLEARANCE  
CRF CASE REPORT FORM  
CTCAE  COMMON TOXICITY CRITERIA ADVERSE EVENT  
CTEP  CANCER THERAPY EVALUATION PROGRAM  
CTO CLINICAL TRIALS OFFICE  
CTSI  CLINICAL AND TRANSLATIONAL SCIENCE INSTIT UTE 
DLI DONOR LYMPHOCYTE INFU SION 
DMSO  DIMETHYLSULFOXIDE  
DNA  DEOXYRIBONUCLEIC ACI D 
DSMP  DATA AND SAFETY MONITORING PLAN 
ECG ELECTROCARDIOGRAM  
EBV  EPSTEIN -BARR VIRUS  
FDA FOOD AND DRUG ADMINISTRATION  
G-CSF GRANULOCYTE -COLONY STIMULATING F ACTOR  
GVHD  GRAFT VERSUS HOST DI SEASE  
GVL GRAFT -VERSUS -LEUKEMIA  
HBV  HEPATITIS B VIRUS  
HCV  HEPATITIS C VIRUS  
HIV HUMAN IMMUNODEFICIEN CY VIRUS  
HLA HUMAN LEUKOCYTE ANTI GEN 
HMA  HYPOMETHYLATING AGEN TS 
HTLV1/2  HUMAN T CELL LYMPHOTROPIC V IRUS 1/2 
IB INVESTIGATOR ’S BROCHURE  
IGG IMMUNOGLOBULIN G 
IRB INSTITUTIONAL REVIEW  BOARD  
IV INTRAVENOUS  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 8 of 54    CPRC #2018LS066  
 
 ABBREVIATION  DEFINITION  
JAK JANUS KINASE  
MCC  MASONIC CANCER CENTER  
MCC -CISS MASONIC CANCER CENTER  - CLINICAL INFORMATICS SHARES SERVICES  
MDS  MYELODYSPLASTIC SYNDR OME 
MPN  MYELOPROLIFERATIVE NEOPLASMS  
MSD  MATCHED SIBLING DONO R 
MUD MATCHED UNRELATED DON OR 
NAT  NUCLEIC ACID TESTING  
NCI NATIONAL CANCER INSTITUTE  
NK NATURAL KILLER CELLS  
NRM  NON-RELAPSE MORTALITY  
ONCORE  ONLINE ENTERPRISE RESEARCH MANAGEMENT ENVIRONMENT  
OS OVERALL SURVIVAL  
PFS PROGRESSION FREE SURVIVAL  
PHI PROTECTED HEALTH INFORMATION  
RFLP  RESTRICTION FRAGMENT LENGTH POLYMORPHISM  
RH RHESUS  
SAE SERIOUS ADVERSE EVEN T 
SOP STANDARD OPERATING P ROCEDURE  
STAT  SIGNAL TRANSDUCER AND ACTIVATOR OF TRANS CRIPTION  
T. Cruzi  TRYPANOSOMA CRUZI 
TTL TRANSLATIONAL THERAPY LAB 
ULN UPPER LIMIT OF NORMAL  
WBC WHITE BLOOD CELL  
WOCBP  WOMEN OF CHILDBEARIN G POTENTIAL  
  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 9 of 54    CPRC #2018LS066  
 
 Synopsis  
Study Design:  This is a multi -center, single -arm, open -label, phase II trial for the frontline  treatment 
of relapsed AML or MDS following allo -HCT.  
 
Eligible subjects will receive up to 4 cycles of combined modality treatm ent. The 
number of cycles depends on response, toxicity, and the r emaining cell dose.  
 
Cycles include:  
• 10 days of decitabine 20 mg/m2 IV daily, or, alternatively  on a 5 -2-5 schedule 
with no weekend infusion. If a CR is achieved after 2 cycles using the 10 -day 
schedule, subsequent cycles will change to a 5-day schedule.  
• Starting with d ay 1 of cycle 1  and continuing for up to 6 mon ths after the end 
of the last cycle, patients will receive ruxolitinib 5 mg twice daily orally. Dose 
may be increased to 10 mg twice daily in cycles 2 through 4 if platelets 
improve to >100 x 109/L. 
• DLI from the original donor  will be infused within 10 days after the last dose 
of decitabine  in each cycle .  
Patients will be screened for ongoing eligibility before each subsequent cycle of 
therapy. Patients with disease progression, new GVHD (except grade I acute  
GVHD), prolongation of the most recent cycle to more than 8 weeks (for any 
reason), or inadequate cell dose for further DLI will not rece ive further treatment 
on study. The DLI dose in each cycle will be determined according  to a donor -
dependent dose -escalation algorithm (schema).  
 
The expected duration of treatment for each subject is 4 cycles of treatm ent, each 
lasting 4 -8 weeks. Subject s will be followed on study for 12 months.  
 
Primary 
Objectives:  Determine the efficacy of combined modality treatment (ruxolitinib, 1 0-day 
decitabine, and DLI) for relapsed AML or MDS post allo -HCT. 
Secondary  
Objectives:  ● Evaluate OS 
● Determine  incidence of grade II -IV acute graft -versus -host disease (aGVHD II -IV)  
● Evaluate PFS  
● Determine  incidence of relapse  
● Evaluate complete remission (CR)  
● Determine  incidence of non -relapse mortality (NRM)  
● Best response  
Correlative 
Objectives:  ● Incidence and severity of adverse events (AEs) and seriou s AEs (SAEs) until 3 
months after day 1 of the last received cycle  
● Correlative studies: T cell and NK cell subset analysis by flow cytometry, 
correlation between TP53  mutation and response, clonal dynamics during and 
after the course of therapy  
Key Inclusion  
Criteria :  ● Age 12 years or older  
● Undergone first allo -HCT from a 6/6 matched sibling donor, 8/8 matched 
unrelated donor, or a n HLA  haploidentical donor.  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 10 of 54    CPRC #2018LS066  
 
 ● AML or MDS  
● Additional cells sufficient for the first DLI available from the same donor  or the 
donor willing to donate  
● Partial (or better) engraftment from the bone marrow showing relapse: Defined 
as >50% donor chimerism on non -split RFLP .   Patients with chimerism of 25 -50% 
may be enrolled with approval of the site PI  and Sponsor/Investigator.  
● Karnofsky Performance Status  ≥ 50%  
● Adequate organ function: Total bilirubin < 1.5 x ULN; AST/A LT < 2.5 x ULN; 
Creatinine clearance ≥40 mL/minute  
● Peripheral white b lood cell count <50 x 109/L   
● Subjects and spouse/partner who are of childbearing poten tial must be using 
highly effective contraception consisting of 2 forms of birth control st arting at 
Screening and continuing through the entire study  
● Male subjects must  not donate sperm during the Screening and Treatment 
Periods, and for at least 3 months after the last dose of ruxolitinib  
Key Exclusion 
Criteria:  ● Active uncontrolled infection.  
● History of infection with human immunodeficiency virus (HIV), unresol ved 
hepatitis B, or hepatitis C  
● Untreated CNS leukemia  
● Untreated  or active GVHD (acute or chronic)  
● History of grade III -IV acute GVHD  
● Any form of iatrogenic immunosuppression except < 0.5 mg/kg/day of 
prednisone or equivalent  
● Unresolved veno -occlusive disease of the liver  
● Subjects who are pregnant, breast feeding or sexually active and  unwilling to use 
effective birth control for the duration of the study  
● Radiation therapy within 14 da ys prior to consent  
● Any prior therapy for relapse after allo -HCT   
● Prior DLI.  CD34 -selected boost is allowed  
● Exposure to any other investigational agent, device or procedure within 2  weeks 
prior to consent  
● Patients or donors  with any medical or psychologic al condition that, in the 
opinion of the Investigator, might interfere with the subject’s particip ation in the 
trial, pose any additional risk for the patient/donor , or confounds the 
assessments of the subject  
● Subjects with known allergies, hypersensitivit y or intolerance to ruxolitinib or 
similar compounds  
Key 
Rescreening  
Inclusion 
Criteria (before 
Cycle 2 -4):  ● Additional cells available from the same donor used for the first DLI or the donor 
willing to donate  
● Karnofsky Performance Status ≥ 50%  
● Adequate organ function: Total bilirubin < 1.5 x ULN; AST/A LT < 2.5 x ULN; 
Creatinine clearance ≥40 mL/minute within 3 days prior to day 1  
● Peripheral white blood cell count <50 x 109/L within 3 days prior to day 1   
Key 
Rescreening  ● Active uncontrolled infection  
● Any new GVHD except grade I acute GVHD during the most recent cycle  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 11 of 54    CPRC #2018LS066  
 
 Exclusion 
Criteria (befo re 
Cycle 2 -4): ● Any form of iatrogenic immunosuppression except <0.5 mg/kg/d ay of 
prednisone or equivalent  
● Unresolved veno -occlusive disease of the liver  
● Subjects who are pregnant, breast feeding or sexually active and  unwilling to use 
effective birth control for the remaining duration of the study  
● Radiation therapy during the most recent cycle  
● Disease progression during the most recent cycle . Screening bon e marrow biopsy 
is required only before cycles 1 and 3.   
● Exposure to any other investigational agent, device or proc edure during the most 
recent cycle  
● Patients or donor  with any medical or psychological condition that, in the opinion 
of the Investigator, might interfere with the subject’s continuation in the trial,  
pose any additional risk for the patient/donor , or confounds the assessments of 
the subject  
● Any condition resulting in prolongation of the most recent cy cle beyond 8 weeks . 
If in the view of the  investigator, postponing the next cycle is justified for any 
reason, this is allowed as long as the current cycle does not exceed 8 weeks. If  
longer than 8 weeks, patients will not receive further therapy on study   
● Consent withdrawal by patient  
Enrollme nt: Approximately 34 subjects will be enrolled  (32 evaluable) over a period of 24 months, 
with an additional 12 months of follow up  
  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 12 of 54    CPRC #2018LS066  
 
 Schema  
 
Potentially Eligible Patients:  
Relapsed AML or MDS post allo HCT  
 
 
Obtain consent and HIPAA  
 
 
 
 
 
Response: BMBX at 4 -6 weeks after Cycle 2 Day 1  and 4-6 
weeks after day 1 of last cycle of decitabine  
 
 
                                             Analyze for primary, secondary, and safety endpoints  
 
 
*DLI dose escalation algorithm  
 MSD  MUD Haploidentical  
DLI #1, x108 CD3/kg  0.1-1 0.05 -0.5 0.01 -0.1 
DLI #2, x108 CD3/kg  0.5-5 0.1-1 0.05 -0.5 
DLI #3, x108 CD3/kg  1-10 0.5-5 0.1-1 
DLI #4, x108 CD3/kg  5-50 1-10 0.5-5 
DLI: Donor lymphocyte infusion; MSD: Matched sibling donor; MUD: Matched unre lated donor  
 
**If CR is achieved after cycle 2, patients will be switched to a 5 day sc hedule.   Ruxolitinib
Twice a Day beginning Day 1, Cycle 1 through 6 
months after the end of final cycle
Up to 4 Cycles (28 Days in cycle)
Day 1 -10 (Or 5 -2-5 schedule) :  Decitabine 1x daily. ** 
Within 10 days after last decitabine dose : DLI per 
dose algorithm* 
Between Cycles (Day 29 -56)
Up to 4 weeks : Continuous rescreening for eligibility 
to continue to additional cycles, or remove from trial 
(due to disease progression, new GVHD, 
prolongation of previous cycle to 8 weeks, or 
inadequte cell dose for further DLI) Research 
Specimen 
collections:
50 mL of 
peripheral 
blood: at 
enrollment, 
before each 
cycle; 30, 90, 
180 days after 
first day of last 
cycle; at time 
of 
progression; 
at GVHD onset
BMBX prior to cycle 1 
(optional), time of 
response assessment 
& at progression
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 13 of 54    CPRC #2018LS066  
 
 1 Objectives  
1.1 Primary Objective  
To determine the efficacy of combined modality trea tment (ruxolitinib, decitabine, 
and DLI) for relapsed AML or MDS post allo -HCT as measured by overall survival (OS) 
at 6 months .  
1.2 Secondary Objectives  
• To evaluate  OS  
• To d etermine  cumulative incidence of grade II -IV acute graft -versus -host disease 
(aGVHD II -IV)   
• To evaluate  PFS  
• To d etermine  incidence of relapse  
• To d etermine complete remission (CR)  
• To d etermine incidence of non -relapse mortality (NRM)  
• To measure b est response  
1.3 Correlative Objectives  
• To evaluate  incidence and severity of adverse events (AEs) and serious AEs (SAEs) 
until 3 months after day 1 of the last received cycle  
• Correlative studies: T cell and NK cell subset analysis by flow cytometry,  
correlation between TP53  mutation and response, clonal dynamics during and 
after the course of therapy  
2 Background  
Although allo -HCT is a curative treatment approach for AML and MDS, relapse continues to 
be the primary cause of death after allo -HCT, with post -relapse 1 -year overall survival of only 
about 20%1,2. Currently there is no standard treatment for post -HCT relapse. Commonly 
practiced approaches include withdrawal of immunosuppressive medications, 
hypomethylating agents, agg ressive chemotherapy, second allo -HCT, targeted therapies, DLI, 
or a combination of these3. We will apply a combination approach as detailed in the following 
sections:  
2.1 DLI 
DLI is mechanistically based on the concept of restoration and augmentation of a g raft-
versus -leukemia (GvL) effect. However, the success of DLI is limited due to low  efficacy 
and high toxicity. As a result, various strategies are implemented to increase DLI 
potency and decrease its toxicity. Examples for the former group of appr oaches include 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 14 of 54    CPRC #2018LS066  
 
 the use of hypomethylating agents (HMA) or lymphodepleting chemotherapy prior t o 
DLI. Lymphodepleting chemotherapy helps with cytoreduction and provides a  favorable 
cytokine niche for the T cells of DLI to expand4. However, the use of lymphodepleting 
chemotherapy before DLI has been associated with high incidence of severe GV HD, the 
major toxicity of DLI5.  
2.2 HMAs  
The use of HMAs before or after DLI is a popular and less toxic approach compared to 
lymphodepleting chemotherapy before DLI . HMAs increase antigen expression by 
leukemia cells and may make them more immunogenic, i.e. primed for a robust GvL 
effect from DLI6,7. A recent retrospective multicenter study by the German Cooperative 
Transplant Study Group using azacitidine prior to DLI in 154 patients with relaps ed AML 
or MDS after allo -HCT showed that this therapy is well -tolerat ed and effective, 
particularly in patients with low disease burden. Overall response was achiev ed in a 
third of the patients and overall survival at 2 years was approximately 30%8. In another 
study using azacitidine prior to DLI in 65  patients with relapse after allo -HCT, there was 
temporary control of leukemia in ~45% of patients, but only 10% achieved a CR9. 
Furthermore, pioneer murine studies by Jaebok Choi have demonstrated that 
azacitidine mitigates GVHD while preserving GVL by peripheral conversion of  
alloreactive effector T cells into regulatory T cells, thus mitigating GVHD with out 
sacrificing GVL effect10. Azacitidine after DLI was recently tested in a phase 1 study to 
prevent develo pment of GVHD11. Azacitidine was administrated on days 4, 6, 8 and 10 
after DLI with dose escalation schedule of 30 –75 mg/m2 in 39 patients with relapsed 
AML after allo -HCT. None of the patie nts developed severe acute GVHD .  
 
3 Study Rationale   
In the proposed study, we add two novelties to the HMA -DLI platform with the goals of 
increasing efficacy and decreasing toxicity. First, while azacitidine is the m ore commonly used 
HMA in combination with DLI, we will replace azacitidine with 1 0-day courses of decitabine. 
This concept is based on two observations: (i) Unprecedented high response r ates (100% in 
the recent report by Washington University investigators) to 10 -day decitabine, particularly 
in TP53 -mutated MDS/AML12, and (ii) In a recent murine study, decitabine, but not 
azacitidine, potentiated the antileukemic activity of hematopoietic stem  and progenitor cell -
derived NK cells. Furthermore, the number of NK cells in the bone marrow was inc reased 
after decitabin e treatment13. The second novelty in this protocol is adding JAK2 inhibitor 
ruxolitinib to the HMA/DLI combination. JAK inhibition has shown clinical ac tivity in the 
treatment of acute GVHD14,15,16. Preliminary studies conducted by Jaebok Choi have shown 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 16 of 54    CPRC #2018LS066  
 
 determined  according to a donor -dependent dose -escalation algorithm (schema). If the 
collected cell dose in the DLI is less than the target dose , the patient will receive those 
collected cells  and subsequently removed from further treatment cycles. These subjects will  
continue to be followed per protocol.  
 
The expected duration of treatment for each subject is 4 cycles of treatment, e ach lasting 4 -
8 weeks.  
 
Approximately 34 subjects will be enrolled ( 32 evaluable) over a period of 24 months, with 
an additional 12 months of follow up.  
5 Patient Selection  
Study entry is open to adult patients regardless of gender , race  or ethnic background . 
While there will be every effort to seek out and include women and minority p atients, the 
patient population is expected to be similar to that of other relapsed AML or MDS  studies 
at the University Of Minnesota  and other participating institutions .  
5.1 Inclus ion Criteria:  
5.1.1 Age ≥12 years  
5.1.2 Have undergone first allo -HCT from a 6/6 matched sibling donor, 8/8 matched 
unrelated donor, or a n HLA  haploidentical donor.  
5.1.3 History of AML or MDS for which allo -HCT was performed. Overlap MPN/MDS 
is included.  
5.1.4 Untreated relapse of the underlying malignancy as defined by >5% of 
malignant blasts (by morphology and/or flow cytometry) in the bone marrow, 
or myeloid sarcoma.  
5.1.5 Additional cells sufficient for the first DLI available from the same donor , or 
the donor must be willing to do nate . Both G -CSF mobilized and unmobilized 
products are allowed and the choice is at the discretion of the treating 
physician.  
5.1.6 Partial (or better) engraftment from the bone marrow showing relapse , 
defined as >50% donor chimerism on non -split RFLP.  Patients  with chimerism 
of 25 -50% may be enrolled with approval of the site PI  and 
Sponsor/Investigator.  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 17 of 54    CPRC #2018LS066  
 
  
5.1.7 Karnofsky performance status ≥ 50% (appendix I) 
 
5.1.8 Adequate organ function within 14 days of study registration defined as:  
• Total bilirubin < 1.5 x upper limit of institutional normal, unless a diagnosis 
of Gilbert’s disease  
• AST/ALT < 2.5 x upper limit of institutional normal  
• Creatinine clearance ≥40 mL/minute as calculated by the Cockcroft -Gault 
formula. Cockcroft -Gault CrCl = (140 -age) * (Wt in kg) * (0.85 if female) / (72 
* Cr).  
 
5.1.9 Peripheral white blood cell count <50 x 109/L. The use of hydroxyurea for 
cytoreduction is allowed and may continue until cycle 2 day 1  
 
5.1.10  Subjects and spouse/partner who are of childbearing potential  must be using 
highly effective contraception consisting of 2 forms of birth control (at le ast 1 
of which must be a barrier method) starting at Screening and continuing 
through the entire study (for at least 3 months after the last dose of ruxoli tinib 
if study treatment is stopped early or subject withdraws consent). Highly 
effective contraception is defined as:  
• Established use of oral, injected or implanted hormonal methods of 
contraception.  
• Placement of an intrauterine device or intrauterine system.  
• Doubl e barrier methods of contraception: condom or occlusive cap 
(diaphragm or cervical/vault caps) with spermicidal 
foam/gel/film/cream/suppository (double barrier method will count 
as 2 forms of contraception).  
 
5.1.11  Male subjects must not donate sperm during the Screening and Treatment 
Periods, and for at least 3 months after the last dose of ruxolitinib.  
 
5.1.12  Subjects are willing and able to give written informed consent and to comply  
with all study visits and procedures.  Parents or legal guardians will consent for 
minors  and minors will be asked to assent, or be given a minor information 
sheet, per institutional IRB requirements . 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 18 of 54    CPRC #2018LS066  
 
 5.2 Exclusion Criteria:  
5.2.1 Active uncontrolled infection at the time of consent. An active uncontrolled 
infection is defined as hemodynamic instability attributable to sepsis or new  
symptoms, worsening physical signs or radiographic findings attributable to  
infection. Persisting fev er without signs or symptoms of infection will not be 
interpreted as an active uncontrolled infection. Subjects with a controlled  
infection receiving definitive therapy for 72 hours prior to enrollment are 
eligible.  
5.2.2  History of infection with human im munodeficiency virus (HIV), unresolved 
hepatitis B, or hepatitis C.  
5.2.3  Untreated CNS leukemia  
5.2.4  Untreated or active GVHD (acute or chronic)  
5.2.5 History of grade III -IV acute GVHD  at any point in time  
5.2.6  Any form of iatrogenic immunosuppression except <0.5 mg/kg/day of 
prednisone or equivalent at the time of consent.  
5.2.7 Unresolved veno -occlusive disease of the liver, defined as persistent bilirubin 
abnormalities not attributable to GVHD and ongoing organ dys function (renal, 
ascites).  
5.2.8 Subjects who are pregnant, breast feeding or sexually active and unwilling t o 
use effective birth control for the duration of the study, as agents in this study 
are in pregnancy category C: Animal reproduction studies have shown an 
adverse effect on the fetus and there are no adequate and well -controlled 
studies in humans, and category D: there is positive evidence of human fetal 
risk based on adverse reaction data from investigational or marketing 
experience or studies in humans.  
5.2.9 Radiation therapy within 14 days prior to consent.  
5.2.10  Any prior therapy for relapse after allo -HCT.  
5.2.11  Prior DLI.  CD34 -selected  boost is allowed  
5.2.12  Exposure to any other investigational agent, device or procedure within 14 
days  prior to consent  
5.2.13  Patients or donor s with any medical or psychological condition that, in the 
opinion of the Investigator, might interfere with the subject’s participati on in 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 19 of 54    CPRC #2018LS066  
 
 the trial, pose any additional risk for the patient/donor , or confounds the 
assessments of the subject.  
5.2.14  Subjects with  known allergies, hypersensitivity or intolerance to ruxolitinib or 
similar compounds.  
6 Donor s 
Additional cells sufficient for a DLI must be available, or the previous donor mu st be 
willing to donate again.  The required total dose of CD3 cells (x108) per recipient’s body 
weight in kg for 4 DLI procedures is 66, 16.6, and 1.66 for matched siblin g, matched 
unrelated, haploidentical donors, respectively. Donor selection will be in compliance with 
21 CFR Part 1271  and institutional guidelines . If request ing additional collections from  the 
previous donor, d onor assessment and consent process will occur per institutional SOPs 
for related donors or per National Marrow Donor Program (BeTheMatch.org)  SOPs for 
matched unrelated donors, in the apheresis center o r similar donor facility.  No study -
specific consent is needed from donors.  
 
For affiliates: affiliate sites may use their institutional guidelines in evaluat ing related  
donor eligibility.  Matched unrelated donors will be evaluated according to institution al 
and/or National Marrow Donor Program guidelines.  The current study does not 
determine any donor -specific eligibility.  
7 Study Registration  
To be eligible for registration to this study, the patient must meet all of the inclusion 
criteria  and none of the exclusion criteria  listed on the eligibility checklist based on the 
eligibility assessment documented in the patient’s medical record .  
 
The eligibility checklist for both the patient and donor will be completed at the time of 
study regist ration . 
7.1 Registration with the University of Minnesota Clinical Trials Office  
Upon completion of the screening evaluation, eligibility checklist and obtai ning 
consent, the Site Study Coordinator or designee will enroll the patient  and donor  in 
OnCore . Complete registration information is found in the study’s Procedures Manual  
for Affiliate Sites.  
 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 20 of 54    CPRC #2018LS066  
 
 Affiliate sites only:  At the time of registration, the signed consent s will be uploaded 
into OnCore as an attachment under the appropriate record (patient or  donor) .  
 
Affiliates are responsible for fulfilling any local registration requirements.  
7.2 Patients Who Do Not Begin Study Treatment  
If a patient is registered to the study and is later found not able to begin study  
treatment (beginning with the ruxolitinib  and decitabine ); the patient will be removed 
from the study and treated at the physician’s discretion . The study staff will update 
OnCore of the patient’s non -treatment status (off study) . The reason for removal from 
study prior to starting study treatmen t will be clearly indicated in OnCore . The patient 
will be replaced to complete enrollment.   
 
MT201 8-07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
June 23, 2021  Page 23 of 54 CPRC #2018LS066  8.1 Chemotherapy  Regimen  
The administration of the preparative regimen will follow institutional drug and 
supportive care guidelines . Dose and/or schedule adjustments consistent with the 
standard of care may be made on an individual patient basis as needed for safety .  
 
Ruxolitinib  5 mg twice daily orally  beginning Day 1  and through  Cycle 1. Consider dose 
increase to 10 mg twice daily in cycles 2 through 4 if platelets recover to over >100 x 
109/L.  Ruxolitinib  will continu e through six months after the completion of the final 
cycle . See section 8.4  for toxicity dose modification.  
 
Decitabine : 20 mg/m2 IV daily, on the following possible schedules: day 1 -10 for 
cycles 1 -2 (alternative: day 1 -5 and day 8 -12 with no weekend infusion ); day 1 -5 for 
cycles 3 -4 (if CR achieved after Cycle 2 ). There are no dose modifications.  
8.2 DLI 
Within 10 days after the last dose of decitabine in  each cycle , a DLI product from the 
previous donor (either remaining from the original transplant unit, or a n ew unit)  will 
be infused . Donor lymphocytes  will be  obtained by lymphapheresis from the same 
allogeneic donor used for transplantatio n. For local related donors, lymphocyte 
collections will be performed using standard automated mononuclear cell collection 
techniques by the University of Minnesota Blood Bank  or study affiliate site ’s 
institutional guidelines . For unrelated donors or non -local related donors, the 
lymphocyte collect ion will be performed at an outside facility according to procedures 
set by the National Marrow Donor Program. If the collection is non -local, coordination 
for the timing of the cell collection and the ability to  transport the cells to the study 
site is required.  Similarly, for local related donors, the timing of collection (same day 
as infusion vs. cryopreserved) is according to the collaborating centers’  institutional 
guidelines.  
 
The duration of DLI will be determined according to the collaborating centers’ 
institutional guidelines .  DLI will be administered according to a donor -dependent 
dose -escalation algorithm ( Table 4). In the absence of new GVHD (any grade), the 
dose of DLI for the next cycle will be higher than the previous cycle. Otherwise, the 
dose will remain the same. DLI will be given without adding immunosuppressive 
medications  and without conditioning . Addition of immunosuppressive medications 
as indicated to treat grade I acute GVHD or other non-GVHD steroid -responsive 
conditions is allowed.   
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 24 of 54    CPRC #2018LS066  
 
 Table 4: DLI dose escalation algorithm  
 MSD  MUD Haploidentical  
DLI #1, x108 CD3/kg  0.1-1 0.05 -0.5 0.01 -0.1 
DLI #2, x108 CD3/kg  0.5-5 0.1-1 0.05 -0.5 
DLI #3, x108 CD3/kg  1-10 0.5-5 0.1-1 
DLI #4, x108 CD3/kg  5-50 1-10 0.5-5 
DLI: Donor lymphocyte infusion; MSD: Matched sibling donor; MUD: Matched 
unrelated donor  
8.3 Monitoring  
During infusions, patients will be monitored for occurrence of untoward effec ts of the 
infusion of allogeneic lymphocytes such as rash, acute allergic reaction, 
bronchospasm, respiratory distress, acute vascular leak syndrome, localized or 
systemic infections.  
8.4 Ruxolitinib Dose modification  
Dose adjustment for ruxolitinib is recommended  (Tabl e 5). 
 
Table 5: Ruxolitinib dose adjustment  
CTCAE grade 3 or greater 
bleeding related to low 
platelets  Non -transfused platelets  
<10 x 109/L 10-50 x 109/L  >50 x 109/L 
Hold. Reassess 2 weeks after 
resolution of bleeding  Hold  5 mg daily  5 mg twice 
daily1 
1For cycles 2, 3, and 4, if platelets improve to >100 x 109/L, a dose increase to 10 mg 
twice daily may be considered.  
8.5 Re-screening  Eligibility for Cycles 2 - 4 
Patients will be screened for eligibility to continue onto  each subsequent cycle of 
therapy.  Patients with disease progression, new GVHD (except grade I acute GVHD), 
prolongation of the most recent cycle to more than 8 weeks (for any reas on), or 
inadequate cell dose for further DLI will not receive further treatment on study.  
Rescreening will be an ongoing process.  When patients meet the eligibility criteria 
outlined below, they may begin subsequent cycles.  
 
Inclusion Criteria (on or before Day 1 of Cycle s 2-4) 
Patients must meet the following criteria within 7 days prior to day 1 of c ycles 2 -4 
unless otherwise noted.  
 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 25 of 54    CPRC #2018LS066  
 
 8.5.1 Stable disease or better on bone marrow biopsy within 7 days before cyc le 3 
(required) and cycles 2 and 4 (if performed). A bone marrow biopsy before 
cycles 2 and 4 is not required.    
8.5.2 Additional cells available from the same donor used for the first DLI or the 
donor willing to donate ( Table 4). This dose will allow for at least one more 
DLI. Both G -CSF mobilized and unmobilized products are allowed. If a sufficient 
number of cells for the next DLI is not available, patients will not receive 
further treatment on study.  
8.5.3 Adequate organ function : 
• Total bilirubin < 1.5 x upper limit of institutional normal, unless a diagnosis  
of Gilbert’s disease  
• AST/ALT < 2.5 x upper limit of institutional normal  
• Creatinine clearance ≥40 mL/minute within 3 days prior to day 1 , as 
calculated by the Cockcroft -Gault formula. Cockcroft -Gault CrCl = (140 -
age) * (Wt in kg) * (0.85 if female) / (72 * Cr).  
8.5.4 Peripheral white blood cell count <50 x 109/L within 3 days prior to day 1 . The 
use of hydroxyurea is allowed and may continue until day 1 of cycle 2.  
 
Exclusion Criteria (on or before Day 1 of Cycle s 2-4) 
Patients must meet the following criteria at the time of screening for the n ext cycle 
unless otherwise noted.  
 
8.5.5 Active uncontrolled infection. An active uncontrolled infection is defined as 
hemodynamic instability attributable to sepsis or new symptoms, worsening 
physical signs or radiographic findings attributable to infection. Persistin g 
fever without signs or sympto ms will not be interpreted as an active 
uncontrolled infection. Subjects with a controlled infection receiving defini tive 
therapy for 72 hours prior to screening are eligible.  
8.5.6 Any new GVHD except grade I acute GVHD during the most recent cycle.  
8.5.7 Any form of  iatrogenic immunosuppression except <0.5 mg/kg/day of 
prednisone or equivalent.  
8.5.8 Unresolved veno -occlusive disease of the liver, defined as persistent bilirubin 
abnormalities not attributable to GVHD and ongoing organ dysfunction (renal , 
ascites).  
8.5.9 Subject s who are pregnant, breast feeding or sexually active and unwilling to 
use effective birth control for the remaining duration of the study.  
8.5.10  Radiation therapy during the most recent cycle.  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 26 of 54    CPRC #2018LS066  
 
 8.5.11  Disease progression during the most recent cycle.   
8.5.12  Exposure to any other investigational agent, device or procedure during the 
most recent cycle.  
8.5.13  Patients or donors  with any medical or psychological condition that, in the 
opinion of the Investigator, might interfere with the subject’s continuation i n 
the trial, pose any additional risk for the patient/donor , or confounds the 
assessments of the subject.  
8.5.14  Any condition resulting in prolongation of the most recent cycle beyond  8 
weeks . If in the view of the investigator, postponing the next cycle is justified 
for any reason, this is allowed as long as the current cycle does not exce ed 8 
weeks. If longer than 8 weeks, patients will not receive further therapy on 
study.  
8.5.15  Consent withdrawal by patient  
8.6 Supportive Care  
Supportive care will be provided per institutional guidelines and  standard of care . The 
investigator may prescribe any concomitant medications or treatment deemed 
necessary to provide adequate supportive care . Supportive care may include 
antibiotics, anti -fungals, analgesics, transfusions, growth factors .  
 
Patients with recent CNS involvement should continue on CNS therapy 
(chemotherapy or radiation) as medically indicated during the protocol.  
8.7 General Concomitant Medication Guidelines    
• Coadministration with potent CYP3A inhibitors; consider alternative ag ents 
with less  CYP3A inhibition  
• Coadministration with potent CYP3A4 inducers.  
• If concomitant administration of an anticoagulant/antiplatelet medication is 
indicated, then caution and enhanced monitoring is required. History of 
thrombocytopenia should be a factor in the  choice of anticoagulant and dose.  
8.8 Duration of Study Treatment  
The expected duration of treatment for each subject is 4 cycles of trea tment, each 
cycle lasting 4  weeks; with up to  4 weeks of rescreening for eligibility to continue on 
to subsequent cycles; followed by six additional months of ruxolitinib .   The following 
may be reasons for removal from additional study  treatment : 
• unacceptable toxicity  
• disease progression   
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 27 of 54    CPRC #2018LS066  
 
 • new GVHD (except grade I acute GVHD)  
• prolongation of the most recent cycle to more than  8 weeks (for any reason)  
• inadequate cell dose for further DLI  
• consent is withdrawn or patient is not compliant  
 
Patients who are unable to receive further DLIs after initial cycle(s), ma y continue to 
receive  ruxolitinib as long as the physician believes they are benefiting from the 
treatment, the patient has not withdrawn consent, and they have not develope d 
unacceptable toxicity . 
 
All patients  receiving at least one cycle of treatment  will be followed per Sections 11.1  
and 11.2   and be evaluable per Section  15. 
 
Patients unable to continue DLI  may be treated per physician’s choice.  These patients 
will still be followed per Sections 11.1  and 11.2 . 
8.9 Duration of Study Participation  
All patients must be followed for 12 months  after the last dose of ruxolitinib for 
disease response and survival  unless  one of the following occurs earlier : 
• consent is withdrawn   
• new anti -cancer treatment is started  (follow for survival only) , 
• patient is discharged to hospice (terminal) care  (follow for survival only)     
9 Expected Adverse Events  and Potential Risks  
9.1 Ruxoliti nib 
Refer to the most current IB for the comprehensive list of adverse events . 
 
The following s severe  events have been seen in patients being treated for 
myelfibrosis or polycythemia vera  and are considered expected:  
 
Very Common (greater than 
or equal to 10%, or 10 or 
more out of 100 people)  Common (between 1 to 
10%, or between 1 and 10 
out of 100 people)  Rare (less than 1 out of 100 
people)  
• Ruxolitinib may cause low 
platelet counts 
(thrombocytopenia), low 
red blood cell counts • Infection  
• chills  
• aches  
• fever  • Progressive multifocal 
leukoencephalopathy  
• Non -Melanoma Skin 
Cancer  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 28 of 54    CPRC #2018LS066  
 
 Very Common (greater than 
or equal to 10%, or 10 or 
more out of 100 people)  Common (between 1 to 
10%, or between 1 and 10 
out of 100 people)  Rare (less than 1 out of 100 
people)  
(anemia), and low white 
blood cell counts 
(neutropenia)  
• unusual bleeding  
• bruising  
• tiredness  
• shortness of breath  
• fever  
• Cholesterol increases  • nausea  
• vomiting  
• weakness  
• painful skin rash or 
blisters  
 
The following severe events  have been seen in patients  being treated for acute or chronic 
GVHD  and are considered expected . 
 
Common for acute 
GVHD ( 1 - 10%)  Uncommon for 
acute GVHD  
(<1%) Common for 
chronic GVHD ( 1-
10%)  Uncommon for 
chronic  GVHD  (<1%) 
• low platelet counts 
(thrombocytopenia), 
and low white blood 
cell counts 
(neutropenia): or 
low red cell, white 
cell, and platelet 
counts 
(pancytopenia)  
• CMV infection  
• Sepsis  • Septic shock  • low red blood cell 
counts (anemia)  • low platelet  counts 
(thrombocytopenia ) 
• Urinary tract 
infection  
• Sepsis  
• Septic shock  
 
9.2 Decitabine   
Refer to the most current IB or package insert(s) for the comprehensive l ist of 
adverse events.  
Very Common (greater than or 
equal to 10%, or 10 or more out 
of 100 people)  Common (between 1 to 
10%, or between 1 and 
10 out of 100 people)  Rare (less than 1 out of 
100 people)  
• low platelet count with 
increased risk of 
bruising/bleeding  • blurred vision  
• pain  
• high blood sugar  
• headache  • confusion  
• trouble sleeping  
• fluid in the lungs  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 29 of 54    CPRC #2018LS066  
 
 Very Common (greater than or 
equal to 10%, or 10 or more out 
of 100 people)  Common (between 1 to 
10%, or between 1 and 
10 out of 100 people)  Rare (less than 1 out of 
100 people)  
• low white blood cell count 
with increased risk of infection  
• low red blood cell count 
(anemia) with symptoms like 
tiredness, low  energy, or 
shortness of breath  
• nausea  
• vomiting  
• diarrhea  
• constipation  
• tiredness  
• fever  
• pain or swelling in the arms or 
legs • bruises or bleeding  
• swollen lymph nodes 
("glands")  
• sores in mouth, on 
tongue, or on lips  
• infection  
• indigestion or sour 
stomach  
• abnormal blood tests 
which suggest that the 
drug is affecting the 
liver  • severe allergic 
reaction, with 
symptoms like 
flush ing, hives, trouble 
breathing or 
swallowing, dizziness, 
swelling of mouth or 
throat (while drug is 
being infused)  
• serious infections  
• death from infection, 
bleeding, or other 
cause  
 
9.3 Risks Due to D LI 
Acute Infusion Reaction Following Donor Lymphocytes  
Although infusion of donor lymphocytes has reportedly not been associated wi th serious 
acute hypersensitivity reactions, patients will be closely watched for the occurrence of 
hypotension, dyspnea and angiodema during the infusion and immediately thereaf ter.  
Corticosteroids should be avoided and acetaminophen and Benadryl may be 
administered as needed.  
 
Acute Graft -Versus -Host Disease  
Infusion of donor lymphocytes into patients who relapse post allogeneic  bone marrow 
transplantation has frequently resulted in development of acute graft -versus -host disease 
with involvement of the skin and liver, often requiring treatment.  Despite tre atment, 
some cases of GVHD have been of high grade and deaths from GVHD have been reported.  
GVHD may occur between 1 and 24 weeks post -infusion of the donor lymphocytes.  
Patients will have regular assessment for development of new or worsening  of existing 
GVHD during the entire study period.  
 
Bone Marrow Aplasia  
After donor lymphocyte infusions, patients may develop aplasia requiring blood product 
transfusions and/or growth factor support.  This has been reported in 10 -15% of reported 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 31 of 54    CPRC #2018LS066  
 
 Incyte Corp oration  will supply Ruxolitinib at no charge to patients participating 
in this clinical trial.  
 
Ruxolitinib will be supplied as 5 mg tablets packaged in 60 -count high -density 
polyethylene bottles.  All tablet excipients comply with the requirements of  
the applicable compendial monographs.  
 
All Incyte product labels will state "Caution: New Drug --Limited by Federal (or 
United S tates) law to investigational use."  
 
The investigator shall take responsibility for and shall take all steps to maint ain 
appropriate records and ensure appropriate supply, storage, handling, 
distribution, and usage of investigational product in accordance with the 
protocol and any applicable laws and regulations.  
 
10.1.4  Storage Requirements  
Bottles of tablets should be stored at room temperatu re, 15°C to 30°C (59°F 
to 86°F).  
 
10.1.5  Preparation and Administration  
Tablets can be taken with or without food. Grapefruit juice should not be 
consumed while on Ruxolitinib.  
 
10.1.6  Drug Accountability and Destruction  
Ruxolitinib must be dispensed only from official study sites and to eligible 
patients under the supervision of the site investigator. Ruxolitinib should be 
stored in a secure area according to local regulations.  It is the responsibility of 
the site investigator to ensure that study drug is only dispensed to patients. 
After final drug reconciliation, unused ruxolitinib will be disposed at the  site 
following procedures fo r the disposal of anticancer drugs.  
10.2 Decitabine  
10.2.1  Other Names  
Dacogen  
 
10.2.2  Product Description  
Dacogen™ (decitabine) for Injection contains decitabine (5 -aza-2’-
deoxy cytydine), an analogue of the natural nucleoside 2’ -deoxycytidine. 
Decitabine is a fine, white to almost white powder with the molecular formula 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 33 of 54    CPRC #2018LS066  
 
 should be further diluted with 0.9% Sodium Chloride Injection, 5% Dextrose 
Injection, or Lactated Ringer’s Injection to a final drug concentration of 0.1 - 
1.0 mg/mL.  
 
Unless used within 15 minutes of reconstitution, the diluted solution must be 
prepared using cold (2°C - 8°C) infusion fluids and stored at 2°C - 8°C (36°F - 
46°F) for up to a maximum of 7 hours until administration.  
 
10.2.6  Stability  
Unless used within 15 minutes of reconstitution, the diluted solution must be 
prepared using cold (2°C - 8°C) infusion fluids and stored a t 2°C - 8°C (36°F - 
46°F) for up to a maximum of 7 hours until administration.  
 
10.2.7  Drug Accountability  
Decitabine is commercially available and will be procured by the inpatient 
pharmacy per institutional guidelines.  
11 Clinical Evaluations and Procedures  
Scheduled evaluations up to Day + 28 in each cycle may be performed +/ -3 days from the 
targeted date; evaluations and procedures (including research related) performed after 
Day + 28 through end of final cycle  may be done +/ -7 days of the targeted  date . Follow -up 
beginning at 6 months may be done +/ - 2 weeks of the targeted date. In addition, targeted 
days may be altered as clinically appropriate.   
MT201 8-07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
June 23, 2021  Page 34 of 54 CPRC #2018LS066  11.1 Required Clinical Care Evaluations  
 Screening within 28 
days of study 
enrollment ( within 14 
days  of C1D1  for 
eligibility labs)  Every Treatment Cycle  
Between study 
cycles (day 29 -
56)3 Post DLI  
Visit  
(4-6 weeks  
after last  
DLI) Follow -Up 
Q 3 months from the  end 
of last cycle  through 12 
months  During 
Decitabine 
admin  Day of DLI  
Written Consent  X      
Medical history  X      
Histological confirmation of diagnosis 
and staging X      
Prior treatment  X      
Physical exam  X X8 X  X X 
Provider assessment  X X8 X    
Weight (Height also during screen)  X X8     
Concomitant medications  X X (day 1 each  
cycle)      
Karno fsky performance status  X   X   
ECG X   X   
Type and Screen (ABO/RH/  Indirect 
Antiglobulin)  X      
Assessment of AEs  X X X  X  
Complete Blood Count with diff (CBC)  X X8 X X X X 
Comprehensive Metabolic Profile 
(CMP)1 X X8 X X X X 
HIV test X      
Hepatitis B and C  X      
Pregnancy test (urine or serum) for 
WOCBP  X2   X   
Bone Marrow biopsy  X4   X5 X  
Relapse/progression status  X   X   
Survival status       X 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 35 of 54    CPRC #2018LS066  
 
  Screening within 28 
days of study 
enrollment ( within 14 
days  of C1D1  for 
eligibility labs)  Every Treatment Cycle  
Between study 
cycles (day 29 -
56)3 Post DLI  
Visit  
(4-6 weeks  
after last  
DLI) Follow -Up 
Q 3 months from the  end 
of last cycle  through 12 
months  During 
Decitabine 
admin  Day of DLI  
Study treatment  
Decitabine   X (day 1 -10 
or day 1 -5 & 
8-12)6     
DLI   X 
(between 
11-21 or 
13 -22)7    
Ruxolitinib   2 times a day     Through 6 months 
post end of last cycle  
Research Nurse visit   Every two weeks   X X 
1CMP to include sodium, potassium, chloride, creatinine, blood urea nitrog en, and liver function tests includ ing AST, ALT, total bilirubin, and alkaline 
phosphatase  
2For women of childbearing potential (WOCBP): urine or serum pregnancy test within 14 days prior to study registration.  If a urine test is positive or cannot be 
confirmed as negative, a serum pregnancy test will be required.  
3Continuous reass essment for eligibility to  proceed to  subsequent cycles  
4Results taken out of window may used as enrollment verification and will not be consi dered a deviation.  
5Required prior to cycle 3 . This sample will not be taken  if not moving on to cycle 3 .  
6Day 1 -5 in cycle 3 and 4 if CR achieved ;  
7Between day 6 and 16 in cycle 3 and 4 if CR achieved   
8 Day 1 of cycle and additional frequency per site institutional guid elines for clinical care. If screening (baseline) labs wer e performed within 7 days of Day 1 of 
treatment, these do not need to be repeated.  For cycle 2 and later, lab work may be performed up to 3 days prior to the day 1 trea tment day.
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 36 of 54    CPRC #2018LS066  
 
 11.2 Patient – Research Related  
Note: if a patient is not abiding by the required clinical care calendar (Section 11.1 ), the collection schedule 
of the toxicity data and research related samples may be altered or discontinue d on an individual patient 
basis, as appropriate.   
 
It is recognized that with novel therapies as used in this study, the timing of pr otocol directed r esearch 
samples may miss important patient specific events. For this reason, up to  3 extra samples for a total of 180 
ml of blood may be drawn at additional time points that are not specified above.  
 
 Prior to 
Cycle 1  Every 
Treatment 
Cycle  Prior 
to 
Cycle 3    Post DLI   
(4-6 weeks 
after last 
DLI) 90 days (+/ - 
7 days)  after 
the last day 
of last cycle  180 days (+/ - 
14 days) 
after the last 
day of last 
cycle  Event Driven  Event Driven  
Day 1  At disease 
progression  At GVHD 
diagnosis  
(+7 days)  
Peripheral blood: 
Four 10 mL heparin 
tubes and one 10 ml 
clot tube   
X1  X4 X X X4 X 
Research bone 
marrow aspirate 
samples (max 10 ml, 
transferred to a 
heparin tube)   
X2 
  
X3  
X4 
   
X4  
1  Prior to decitabine and ruxolitinib administration  
2 Optional , Adult patients only  
3 This sample will not be taken  if not moving on to cycle 3  
4 At the time of clinical biopsy . If disease progression research samples are taken prior to the post -DLI samples, 
additional samples are not needed  
 
11.2.1  Correlative Studies   
Blood and Bone Marrow samples should be  shipped the day of collection (Monday -Thursday) for next 
day delivery to the Masonic Cancer Center’s Translational Therapy Lab (T TL). Refer to the Laboratory 
Manual for additional details.  Pre-cycle 1  bone marrow sample is optional as it requires patient to 
undergo additional biopsy, while subsequent research b one marrow samples will be collected when the 
patient is having a bone marrow biopsy as part of clinical care.  
 
TTTL will process the samples  to obtain mononuclear cells  (MNC)  and serum/plasma. TTL will analyze 
MNC by flow cytometry to evaluate NK cells for possible effects of therapy on phenotype and functional 
characteristics. Remaining MNC will be cryopreserved for batch analysis of ef fects on T cells and for other 
future testing.  
 
Potential mechanisms of action for JAK/STAT inhibition in the prevention of G VHD and augmentation of 
GVL include alterations in cytokine signaling, alterations in T -cell trafficking through CXCR3 expression, 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 37 of 54    CPRC #2018LS066  
 
 effects on cellular differentiation, and effects on antigen presenting cell function. A n exploratory 
objective of this study will be to evaluate the effects of the combination on im mune effectors and to 
measure changes in biomarkers of GVHD and GVL. To address thi s objective, c orrelative studies may 
include: cellular phenotyping; leukemia antigen expression; cytokine and other soluble biomarker 
expression; chemokine receptor expression and RNA transcript analysis. DN A samples may be used to 
test for genetic associations of response to therapy or GVHD. These s tudies will be performed at 
Washington University at  the end of study using batch analysis of banked  samples . Remaining 
cryopreserved samples  may be used for future research studies at the discretion of the princip le 
investigator.  
11.3 Donor  – Recommended Standard of Care  
Individual institutions may use local SO Ps and clinical care guidelines , and unrelated donors will be 
screened through the NMDP . 
12 Adverse Event Monitoring, Documentation, and Reporting  
Toxicity and adverse events will be classified and graded according to NCI' s Common Terminology Criteria 
for Adverse Events V 5.0 (CTCAE) and reported on the schedule below . A copy of the CTCAE can be 
downloaded from the CTEP home page 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#c tc_50 ). 
 
The following definitions of adverse events (AEs) and serious adverse e vents (SAEs) will determine whether 
the event requires expedited reporting via the OnCore SAE Report Form in additio n to routine 
documentation in the OnCore AE case report form (CRF) .  
 
The reporting timeframes for SAEs, product related issues, and other  reportable events are located in 
Section  12.3 .   
 
Note:  throughout this secti on the generic term “study drug” refers to the study related treatment (the 
ruxolitinib, decitabine, and DLI ). 
12.1 Adverse Event Terminology  
The following definitions are based on the Code of Federal Regulations Titl e 21 Part 312.32 
(21CFR312.32(a)).  
 
Adverse Event:   Any untoward medical occurrence associated with the use of a drug in humans, w hether 
or not considered drug related.  
Suspected Adverse Reaction:   Any adverse event for which there is a reasonable possibility that the drug  
caused the adverse event.  For the purposes of IND safety reporting, "reasonable possibility" means t here 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 38 of 54    CPRC #2018LS066  
 
 is evidence to suggest a causal relationship between the drug and the adverse ev ent. Suspected adverse 
reaction implies a lesser degree of certainty about causality than adverse re action, which means any 
adverse event caused by a drug.  
 
Life-Threatening Adverse Event Or Life -Threatening Suspected Adverse Reaction:  An adverse event or 
suspected adverse reaction is considered “life -threatening” if, in the view of either the invest igator or 
sponsor, its occurrence places the patient or subject at immediate risk of dea th. It does not include an 
adverse event or suspected adverse reaction that, had it occurred in a m ore severe form, might have 
caused death.  
 
Serious Adverse Event Or Serious Suspected Adverse Reaction:   An adverse event or suspected adverse 
reaction is considered “serious” if, in the view of either the investigat or or sponsor, it results in any of 
the following outcomes:  
• Death  
• A life -threatening adverse event  
• Inpatient  hospitalization or prolongation of existing hospitalization  
• A persistent or significant incapacity or substantial disruption of the abi lity to conduct normal life 
functions  
• A congenital anomaly/birth defect  
• An important medical event  
Important medical eve nts that may not result in death, be life -threatening, or require hospitalization 
may be considered serious when, based upon appropriate medical judgment, they  may jeopardize the 
patient or subject and may require medical or surgical intervention to preven t one of the outcomes 
listed in this definition  
 
Unexpected adverse event or unexpected suspected adverse reaction:  An adverse event or suspected 
adverse reaction is considered “unexpected” if it is not listed in the investiga tor brochure or is not listed 
at the specificity or severity that has been observed; or, if an investigator  brochure is not required or 
available, is not consistent with the risk information described in the general i nvestigational plan or 
elsewhere in the current application, as amend ed.  
 
Expedited (Rapid) Reporting:  Certain events may require rapid notification to entities providing patie nt 
safety oversight (e.g. IRB) as detailed in Section 1 2.3. For the IRB this is 5 business days from discovery.  
The categories for AE attribution to study treatment are as follows:   
• Definite – clearly related  
• Probable – likely related  
• Possible – may be related  
• Unlikely – doubtfully related  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 39 of 54    CPRC #2018LS066  
 
 • Unrelated – clearly not related  
 
The following definitions are from the Masonic Cancer Center’s Standard Op erating Procedure (SOP) 
Deviation Reporting:  
Major Deviation:  A deviation or violation that impacts the risks and benefits of the resea rch; may impact 
subject safety, af fect the integrity of research data and/or affect a subject’s willingness to pa rticipate in 
the research. Deviations that place a subject at risk, but do not resu lt in harm are considered to be major 
deviations.  
 
Minor Deviation:  A deviation or violation that does not impact subject safety, compromise t he integrity 
of research data and/or affect a subject’s willingness to participate in the res earch.  
12.2 AE Documentation  
AE reporting will occur via data entry into the study eCRF.  AEs reported through expedite d processes 
(e.g., reported to Incyte , IRB, FDA, etc.) must also be reported in routine study data submissions .  Patients 
will be monitored for adverse events after the subject has signed the ICF  through 30 days after the last 
dose of  study drug . Adverse events  recorded in the eCRFs  include the following:  
 
• CTCAE grade 3 and greater allergic reactions related to ruxolitinib or decitabine  occurring until 
30 days after the last treatment on study  
• CTCAE grades 3 and greater organ toxicity (cardiac, dermatologi c, gastrointestinal, hepatic, 
pulmonary, renal/genitourinary, or neurologic) occurring until 30 days aft er the last treatment 
on study  
• aGVHD III -IV occurring until 3 months  after the last  cycle of  treatment  
• CTCAE grade 4 neutropenia lasting more than 14 d ays, occurring until 30 days after the last 
treatment on study  
• CTCAE grades 3 and greater febrile neutropenia, or grade ≥ 3 neutropenia with documented 
infection , occurring until 30 days after the last treatment on study  
• CTCEA grade 4 thrombocytopenia lasting more than 14 days if pre -treatment platelet count > 100 
x 109/L, occurring until 30 days after the last treatment on study  
 
In addition any event meeting the definition of a serious adverse event (SAE)  regardless of attribution 
that occurs during this period will be documented in the source document and rec orded in OnCore.  
 
After the final treatment visit, monitoring for adverse event will become  less frequent based on the 
schedule in Section 11 and only events at least possibly related to study treatment (based on the ta ble 
above) will be documented upon knowledge.  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 40 of 54    CPRC #2018LS066  
 
 12.3 SAE Documentation  and MCC Reporting Requirements  
Individual institution reporting requirements are listed in section 12.5 .  
 
All SAEs are documented using the MCC OnCore SAE Report Form and reported w ithin the timeframes 
indicated below:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Agency  Criteria for reporting  Timeframe  Form to 
Use Submission 
address/ fax 
numbers  
U of MN 
IRB Events requiring prompt reporting including, but not 
limited to unanticipated death of a locally enrolled 
subject(s); new or increased risk; any adverse event  
that require a change to the protocol or consent 
form or any protocol deviation that resulting i n 
harm  For a complete list refer to 
http://www.research.umn.edu/irb/guidance/ae.htm
l#.VC7xraI0 -sh  Within 5 
business 
days of 
event 
discovery  
 MCC SAE 
Report 
Form  ETHOS  
 
copy SAEs to 
Incyte  at  
SafetyReporting
@incyte.com  
(note: Incyte 
does not need 
copies of 
deviations)  Deviations from the protocol, per current IRB 
reporting requirements  Deviation 
Report  
FDA  Unexpected and fatal or unexpected and life 
threatening suspected adverse reaction  no later than 
7 Calendar 
Days  
MCC SAE 
Report 
Form  Submit to FDA as 
an amendment to 
IND 
1) Serious and unexpected suspected adverse 
reaction or  
2)  increased occurrence of serious suspected 
adverse reactions over that listed in the protocol or 
investigator  brochure or  
3) findings  from other sources (other studies, animal 
or in vitro testing)  no later than 
15 Calendar -
Days  
Events that trigger an  early study stopping rule.  no later than 
7 Calendar 
Days  Event 
Form  
Incyte 
Corporation  Every SAE, regardless of suspected causality (eg, 
relationship to study drug(s) or study procedure or 
disease progression), occurring after the subject has 
signed the ICF through the last study visit (or 30 
days) after the last dose of study drug, whichever is 
later) must be reported to the Incyte wi thin 24 
hours of learning of its occurrence, Incyte may 
request follow -up and other additional information 
from the Sponsor Investigator.  Within 24 
hours of 
event 
discovery  MCC SAE 
Report 
Form  SafetyReporting@
incyte.com  
Masonic 
Cancer 
Center  
SAE 
Coordinator  Events that count toward early study stopping rule.  At time of 
reporting  Event 
Form  SAE Coordinator  
mcc-
saes@umn.edu  
with copy to 
Incyte  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 41 of 54    CPRC #2018LS066  
 
 Expedited SAE Reporting Requirements :   
Report Within 24 Hours:  SAEs must be reported expeditiously to the Masonic Cancer Center Affiliate 
Sites Manager within 24 hours of knowledge .  
12.4 Early Stopping Rule Events Documentation and Reporting Requirements  
The following events count toward an early study stopping rule per Section 1 5.4 and must be reported 
to the MCC Affiliate Sites Manager and to Incyte Pharmaceuticals  using the Event Form found OnCore  
under the reports tab:  grade III -IV aGVHD until 3 months after the last cycle of treatment . 
 
An event that counts toward an early stopping rule does not necessarily constitut e a SAE and should be 
reported as such only if they meet the criteria for reporting as defined in Section  12.3. 
12.5 Institutional Event Reporting Table  
Individual institutional sites will be responsible for reporting any event mee ting local reporting 
requirements to their institutional IRB and/or other research oversight commit tees.  
 
Institutional sites will be responsible for report ing events as defined  in sections 12.1 , 12.2 , 12.3  and 12.4  
within the following time frames to the MCC Affiliate Sites Manager  
 
Event Type  Reporting Timeframe  OnCore Form 
to Use  Report to ** 
Any event 
meeting the 
definition of a 
SAE  occurring 
after the subject 
has signed the 
ICF through the 
last study visit 
(or 30 days after 
the last dose  of 
study drug, 
whichever is 
later)  Within 24 hours of 
knowledge  SAE Report 
Form  
Masonic Cancer Center (MCC) 
Affiliate Sites Manager  
affiliates@umn.edu  
 
The affiliate manager will submit 
SAEs to Incyte 
(SafetyReporting@incyte.com  )  
 
Local institutional I RB or other 
entities per institutional policies 
and guidelines  Stopping Rule 
Events as 
defined in 
section 12.4  Within 24 hours of 
knowledge  Stopping Rule 
Event Form  
Major and 
Critical Clinical 
Deviations , as 
defined in 
Section 12.1 . Within 5 working days 
of knowledge  Deviation 
Report Form  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 42 of 54    CPRC #2018LS066  
 
 Event Type  Reporting Timeframe  OnCore Form 
to Use  Report to ** 
Minor 
Deviations, as 
defined in 
Section 12.1 . Per Institutional Policy  n/a (record in 
Deviations 
Tab) but it is 
not necessary 
to report the 
event to MCC  For UMN MCC only: minor 
deviations are reported to the UMN 
IRB by the study’s regulatory 
specialist per IRB reporting 
requirements.  
 
For Affiliate Sites: minor deviations 
are not reportable to the Masonic 
Cancer Center. Report to local 
institutional IRB or other entities 
per institutional policies and 
guidelines.  
**events occurring at the University of Minnesota are reported to the st udy’s Regulatory Specialist who will submit  Incyte  and other 
entities as usual  
13 Study Data Collection and Monitoring  
13.1 Data Management  
This study will collect regulatory and clinical data using University of Minne sota CTSI’s instance of 
OnCore® (Online Enterprise Research Management Environment).  
 
The Oncore database resides on dedicated secure and PHI compliant hardware c onsisting of 3 physical 
servers: dev, DR, and production. The dev server is located in the Univ ersity of Minnesota (UMN) 
datacenter (WBOB) and houses six database instances (test, tra in, sandbox, mcc reports, oncdm, and 
vendor) that are backed up locally because the data is refreshed from O ncore production data. The 
production server is located in the UMN datacenter (WBOB). All the data serv ers are managed by the 
Academic Health Center  – Information Systems (AHC -IS) virtual servers which utilize clustered 
infrastructure to provide real -time failover of virtual servers. This real -time clustering is physically limited 
to the UMN data center. All relevant AHC IS procedures related for PHI compliant se rvers (as required 
by the Center of Excellence for HIPAA Data) apply to Oncore databases.  
 
The integrated data will be stored in PHI compliant servers managed by AHC IS w ith access given to those 
authorized users in the Clinical and Translation  Science Institute Informatics team (CTSI BPIC and MCC 
CISS). The data will be integrated and extracted to researchers through the C TSI Informatics team and 
will be delivered through secure and compliant mechanisms (e.g. AHC IE data s helter, BOX, sftp, etc ). If 
data de -identification is needed, then compliant AHC IE data de -identification tools will be used. The 
informatics team will grant the IRB approved study team members access to d ata. 
 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 43 of 54    CPRC #2018LS066  
 
 Additional data about correlative laboratory samples generated by the Masonic Cancer Center 
Translational Therapy Laboratory (TTL) from the protocol -directed correlative research samples is stored 
in their Laboratory Information Management System (LIMS).The LIMS databas e application is also stored 
on a production server located in the UMN datacenter (WBOB) and is managed by the Academic Health  
Center  
 
Key study personnel are trained on the use of OnCore and will comply with pro tocol specific instructions 
embedded within the OnCore.  
13.2 Case Report Forms  
Participant data will be collected using protocol specific electronic case report forms (e -CRFs) developed 
within OnCore  based on its  library of standardized forms . The e -CRF will be approved by the study’s 
Principal Investigator and the Biostatistician prior to release for use . The Study Coordinator or designee 
will be responsible for registering the patient into OnCore  at time of study entry, completing e -CRFs 
based on the patient specific calendar, and updating the patient record until patient dea th or end of 
required study p articipation .  
13.3 Data and Safety Monitoring Plan (DSMP)  
The study’s Data and Safety Monitoring Plan will be in compliance with the Univers ity of Minnesota 
Masonic Cancer Center's Data & Safety Monitoring Plan (DSMP), which can be ac cessed at 
https://z.umn.edu/dsmp . 
 
For the purposes of data and safety monitoring, this study is classified as high risk . Therefore the 
following requirements will be fulfilled:  
 
 At least bi-annual  review of the study’s progress by the Masonic Cancer Center Data and  Safety 
Monitoring Council (DSMC).  
 The PI will comply with at least twice yearly monitoring of the project by the  institution’s  monitoring 
services.  
 The PI will oversee the submission of all reportable adverse events per Section  12.3  to the Masonic 
Cancer Center’s SAE Coordinator, the University of Minnesota IRB, and th e FDA .  
 The PI with the CTO has oversight responsibility for trial monitoring at affi liate sites . 
 
In addition, at the time of the continuing review with the University of Minn esota IRB, a copy of the 
report with any attachments will be submitted to the Cancer Protocol Review Co mmittee (CPRC).  
 
 
 
 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 44 of 54    CPRC #2018LS066  
 
 IND Annual Reports  
In accordance with regulation 21 CFR § 312.33, the Sponsor -Investigator will submit a progress report 
annually. The report will be submitted within 60 days of the anniversary date that t he IND went into 
effect.  
13.4 Teleconferences – Lead Site and Affiliate  Site  
Regular teleconferences to facilitate communication between participat ing sites regarding the study’s 
progress, patient updates, summary of safety reports, case report form  completion, and other issues for 
discussion. The University of Minnesota Affiliate Manager will be responsible for arranging these 
teleconferences and preparing the agenda. Meetings will occur at least eve ry 3 weeks; however, these 
may be scheduled more or less frequently at the discretion of the lead instituti on. Participation of a 
mini mum of one representative from each affiliate site will be required. These tel econferences are in 
addition to other previously described site interactions including centra lized patient registration, 
institutional and MCC required reporting of safety related issues, case repo rt form completion in the 
study’s central database (OnCore) and affiliate oversight through self -monitoring in compliance with the 
Masonic Cancer Center’s Data and Safety Monitoring plan.  
13.5 Affiliate Site Monitoring  
The PI ( Dr. Juckett ) with the CTO has oversight responsibility for trial monitoring at affiliate sites . Affiliate 
sites must self -monitor following the University of Minnesota Masonic Cancer Center Data  and Safety 
Monitoring Plan (DSMP - http://z.umn.edu/dmsp ).  
 
The investigator will permit study -related monitoring, audits, and inspections by the study’s Principal 
Investigator or any designees, the local IRB, government regulatory b odies, and University of Minnesota 
compliance groups . The investigator will make available all st udy related documents (e.g. source 
documents, regulatory documents, data collection instruments, study data, etc.) . The investigator will 
ensure the capability for inspections of applicable study -related facilities (e.g. pharmacy, diagnostic 
laboratory, etc.) will be available for trial related monitoring, audits, or regulatory inspectio ns. 
13.6 Record Retention  
The investigator will retain study records including source data, copies o f case report form, consent forms, 
HIPAA authorizations, and all study corre spondence in a secured facility  for at least 6 years after the study 
file is closed with the IRB .  
 
Please contact the CTO before destroying any study related records.  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 45 of 54    CPRC #2018LS066  
 
 14 Study Endpoints  
14.1 Primary Endpoint  
Efficacy is measured by overall survival (OS) at 6 months .  
14.2 Secondary Endpoints  
Secondary endpoints of safety and efficacy are measured as  below.  
• OS at 12 months  
• Cumulative incidence of grade II -IV acute graft -versus -host disease (aGVHD II -IV) at 3 months  
• PFS at 6 and 12 months in patients  
• Cumulative inc idence of relapse at 6 and 12 months  
• Complete remission (CR) at 6 and 12 months  
• Cumulative incidence of non -relapse mortality (NRM) at 6 and 12 months  
• Best response  until next line of treatment, death, or last follow up, whichever occurs soo ner 
14.3 Correlative  Endpoints  
• Incidence and severity of adverse events (AEs) and serious AEs (SAEs) unt il 3 months after day 1 
of the last received cycle  
• Correlative studies: T cell and NK cell subset analysis by flow cytometry, c orrelation between 
TP53  mutation a nd response, clonal dynamics during and after the course of therapy  
15 Statistical Considerations  
15.1 Objectives and Study Design  
This is a single -arm, open -label, multi -center modified Simon’s two -stage phase II trial of a combined 
modality treatment for relapse d AML and MDS after allo -HCT. The primary endpoint is 6  month  OS 
measured from day 1, cycle 1 . We expect a total of 34 enrolled subjects will allow us to obtain 32 
evaluable patients . 
 
Patients are considered evaluable if they receive the first dose of decitabine  and ruxolitinib. All other 
patients will be replaced.  
15.2 Statistical Analysis  
 
Analysis of the Primary Endpoint  
Overall survival will be estimated by Kaplan -Meier curves along wit h 95% confidence bands to provide 
precision.  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 46 of 54    CPRC #2018LS066  
 
  
Secondary and exploratory analysis  
Analysis of secondary endpoints will be primarily descriptive. P rogression -free survival will be estimated 
by Kaplan -Meier curves. Cumulative Incidence will be used to estimate the probability of relapse and 
acute GVHD, treating non -event death as a competing risk. Likewise, relapse will be treated as a 
competing risk when estimating the probability of non -relapse mortality. Response and the number of 
patient in complete  remission will be estimated with simple proportions. Summary statistics usi ng 
frequencies and proportions of patients will be used to assess adverse and s evere adverse events  and 
medians, ranges and descriptive plots for immune therapy . The correlation be tween TP53  mutation and 
response will be assessed with a chi -square test or Fisher’s exact test depending on expected cell 
frequencies. Similar statistics will be used for the correlation against clonal dyn amics curing and after 
the course of therapy.  
 
Subgroup Analysis  
We will assess subgroup analysis of endpoints by donor type. Overall survival is not assumed to differ by 
donor type and this trial is not powered to determine differences within subgroups a nd will therefore 
be considered exploratory.  
 
15.3 Sample Size  
This study is designed as a two -stage phase II trial to estimate OS.  Since the goal is to estimate the OS 
at a long -term time -point (6 months), our design is a generalization of the Simon design. Rather th an 
suspension of the trial for evaluation after stage 1, this design uses a n optimal interim analysis for futility 
without suspension of accrual as proposed by Huang et al17. The goal of this design minimizes the 
expected sample size under the assumed parameters. Our tri al assumes that a 6-month OS of 25% is 
unacceptably low and  a 6-month OS of 50% is a rate worthy of further study. Both the null and alternative 
hypotheses assume that the OS follow an exponential distribution. Given an  overall one -sided type I 
error of 5% , 32 evaluable patients will provide 80% statistical power.  
 
When 14 patients have been enrolled (stage 1), it is expected that the accrual wi ll stop if the 6 month 
Kaplan -Meier estimate of OS is less than 30.0 %. It is not required that the 14th patient be  followed for 6 
months prior to making a decision of whether to continue the trial. Once the 14 th patient has been 
enrolled, the statistician can calculate survival to determine if it falls below th e cut -point. If the trial 
reaches the end of stage II afte r 32 evaluable patients, significant clinical activity would require at least 
a 6 month Kaplan -Meier estimate of OS of 39.2 %. The probability of stopping at the interim analysis 
under the null hypothesis is 63.5% and 10.9% under the alternative hypothesi s. The R package 
‘Optinterm’ with functions ‘OptimDes’ and ‘SimDes’ were used to create design parameters. Assuming 
that 5% of enrolled patients are not evaluable, we expect recruitment of 34 patients.  
 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 47 of 54    CPRC #2018LS066  
 
 Accrual  
We perform approximately 30 DLIs per year at the collaborating institutions combined. Considering 
~50% screen failures and enrollment on competing trials, we expect to compl ete enrollment  in 
approximately 2 years with an additional  year  of follow up after the last patient  has been enrolled . 
15.4 Stopping Rules     
Toxicity Monitoring and stopping rules  
Monitoring guidelines are developed to monitor excess toxicity using a contin uous monitoring strategy 
based on an adaptation of Pocock stopping boundaries20. In the event that a stopping rule is triggered, 
enrollment will be halted and reviewed by the full study committee and if appropria te by the IRB, prior 
to initiation of re -enrollment.  Additionally, the FDA will be informed if a stopping rule is triggered. The 
stopping rule was calculated using the following website: 
http://cancer.unc.edu/biostatistics/program/ivanova/ContinuosM onitoringForToxicity.a spx 
 
Grade III -IV aGVHD until  3 months after the last cycle of treatment  
Stopping rules were developed for excessive grade III-IV aGVHD. Previous results from trials of HMA plus 
DLI have reported an incidence of ~10% for aGVHD III -IV8,9,18,19. The goal is to construct a boundary based 
on aGVHD grade III -IV such that the probability of early stopping is at most 5% if the true rate is equal to 
10% and our sample size is  34. Given these parameters, the upper stopping boundary for aGVHD grade 
III-IV is 2 events out of 2 patients, 3 out of 6, 4 out of 1 0, 5 out of 15, 6 out of 21, 7 out of 27 or 8 out of 
33. The probability of early stopping from excessive aGVHD grade III -IV if the true probability is 30% is 
86%.  
16 Ethical and Regulatory Considerations  
16.1 Good Clinical Practice  
The study will be conducted in accordance with  the appropriate regulatory requirement(s) . Essential 
clinical documents will be maintained to demonstrate the validity of the study and the integrity of the 
data collected . Master files should be established at the beginning of the study, maintained for the 
duration of the study and retained according to the appropriate regulations .  
16.2 Ethical Consid erations  
The study will be conducted in accordance with ethical principles founded in th e Declaration of Helsinki . 
The IRB will review all appropriate study documentation in order to safeguard th e rights, safety and well -
being of the patients . The study wi ll only be conducted at sites where IRB approval has been obtained . 
The protocol, informed consent, written information given to the patients, s afety updates, annual 
progress reports, and any revisions to these documents will be provided t o the IRB by the investigator .  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 48 of 54    CPRC #2018LS066  
 
 16.3 Informed Consent  
All potential study participants will be given a copy of the IRB -approved consent to review. The 
investigator or designee will explain all aspects of the study in lay language  and answer all questions 
regarding the study. If the participant decides to participate in the study, he/she  will be asked to sign 
and date the consent document. Patients who refuse to participate or who withdraw from the study will 
be treated without prejudice.   
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 49 of 54    CPRC #2018LS066  
 
 17 References   
1  Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R et al. Treatment , risk factors, and 
outcome of adults with relapsed AML after reduced intensity conditioning for all ogeneic stem cell 
transplantation. Blood 2012; 119: 1599 –606.  
2  Bejanyan N, Weisdorf DJ, Logan BR, Wang H -L, Devine SM, de Lima M et al. Survival of Patients with Acute 
Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantatio n: A Center for 
International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transp lant 2015; 21. 
doi:10.1016/j.bbmt.2014.11.007.  
3  Rashidi A, Weisdorf DJ, Bejanyan N. Treatment of relapsed/refractory acute myelo id leukaemia in adults. 
Br J Haematol 2018. doi:10.1111/bjh.15077.  
4  Guillaume T, Gaugler B, Chevallier P, Delaunay J, Ayari S, Clavert A et al. Escalated lymp hodepletion 
followed by donor lymphocyte infusion can induce a graft -versus -host respon se without overwhelming 
toxicity. Bone Marrow Transplant 2012; 47: 1112 –7. 
5  Miller JS, Weisdorf DJ, Burns LJ, Slungaard A, Wagner JE, Verneris MR et al. Ly mphodepletion followed by 
donor lymphocyte infusion (DLI) causes significantly more acute graft -versus-host disease than DLI alone. 
Blood 2007; 110: 2761 –3. 
6  Sánchez -Abarca LI, Gutierrez -Cosio S, Santamaría C, Caballero -Velazquez T, Blanco B, Herrero -Sánchez C 
et al. Immunomodulatory effect of 5 -azacytidine (5 -azaC): potential role in the transplantat ion setting. 
Blood 2010; 115: 107 –21. 
7  Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S et al. Tolerability and Clinical Act ivity of Post -
Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leuk emia Treated on the RICAZA 
Trial. Biol Blood Marrow Transplant 2016; 22: 385 –390.  
8  Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK et al. Treatmen t of acute myeloid leukemia or 
myelodysplastic syndrome relapse after allogeneic stem cell transplantation  with azacitidine and  donor 
lymphocyte infusions --a retrospective multicenter analysis from the German Cooperative Transp lant Study 
Group. Biol Blood Marrow Transplant 2015; 21: 653 –60. 
9  Steinmann J, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L et al. 5 -Azacytidine and DLI can induce 
long -term remissions in AML patients relapsed after allograft. Bone Marrow Transplant 201 5; 50: 690 –5. 
10 Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E et al. In vivo admini stration of hypomethylating 
agents mitigate graft -versus -host disease without sacrificing graft -versus -leukemia. Blood 2010; 116: 129 –
139.  
11 Ghobadi A, Choi J, Fiala MA, Fletcher T, Liu J, Eissenberg LG et al. Phase I study o f azacitidine following 
donor lymphocyte infusion for relapsed acute myeloid leukemia post alloge neic stem cell transplantation. 
Leuk Res 2016; 49: 1 –6. 
12  Welch JS, Petti AA, Miller CA, Fronick CC, O’Laughlin M, Fulton RS et al. TP53 and Decitabine in Acute 
Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med 2016; 375:  2023 –2036.  
13  Cany J, Roeven MWH, Hoogstad -van Evert JS, Hobo W, Maas F, Franco Fernandez R et al. Decitabine 
enhances targeting of AML cells by CD34+ progenitor -derived NK cells in NOD/SCID/IL2Rgnull mice. Blood 
2018; 131: 202 –214.  
14  Spoerl S, Mathew NR, Bscheide r M, Schmitt -Graeff A, Chen S, Mueller T et al. Activity of therapeutic JAK 
1/2 blockade in graft -versus -host disease. Blood 2014; 123: 3832 –3842.  
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 50 of 54    CPRC #2018LS066  
 
 15  Carniti C, Gimondi S, Vendramin A, Recordati C, Confalonieri D, Bermema A et al. Pharmac ologic 
Inhibition  of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving G VT Effects. 
Clin Cancer Res 2015; 21: 3740 –3749.  
16  Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas -Bauer K, Metzelder SK et al. Ruxolitinib in 
corticosteroid -refractory gr aft-versus -host disease after allogeneic stem cell transplantation: a multicenter 
survey. Leukemia 2015; 29: 2062 –2068.  
17  Huang B, Talukder E, Thomas N. Optimal two -stage phase II designs with long -term endpoints. Stat 
Biopharm Res 2010; 2: 51 –61. 
18  Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T et al. Azacitidin e and donor lymphocyte 
infusions as first salvage therapy for relapse of AML or MDS after allogeneic  stem cell transplantation. 
Leukemia 2013; 27: 1229 –1235.  
19  Schroeder T, Rautenberg C, Krüger W, Platzbecker U, Bug G, Steinmann J et al.  Treatment of relapsed 
AML and MDS after allogeneic stem cell transplantation with decitabine and DLI —a retrospective 
multicenter analysis on behalf of the German Cooperative Transplant Study Gro up. Ann Hematol 2018; 97: 
335–342.  
20 Ivanova, A., Qaqish, B.F., and Schell, M.J. (2005). Continuous toxicity mo nitoring in phase II trials in 
oncology. Biometrics 61: 540 -545 
 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 51 of 54    CPRC #2018LS066  
 
 Appendix I – Karnofsky Performance Status Scale 
 
Percentage   
100 Normal, no complaints, no evidence of disease  
90 Able to carry on normal activity; minor signs or symptoms of disease  
80 Normal activity with effort; some signs or symptoms of disease  
70 Cares for self; unable to carry on normal activity or do activ e work  
60 Requires occasional assistance, but is able to care for most of h is/her needs  
50 Requires considerable assistance and frequent medical care  
40 Disabled; requires special care and assistance  
30 Severely disabled, hospitalization indicated . Death not imminent  
20 Very sick, hospitalization necessary, active supportive treatment nece ssary  
10 Moribund, fatal processes, progressing rapidly  
0 Dead  
 
REFERENCE    
Karnofsky DA:  Meaningful clinical classification of therapeut ic responses to anti-cancer drugs . Editorial:  Clin Pharmacol Ther  2:709- 712, 1961.  
 
MT2018 -07: ruxolitinib, decitabine, and DLI for post -transplant relapse of AML or MDS  
 
   
February 25, 2022  Page 52 of 54    CPRC #2018LS066  
 
 Appendix II –– GVHD Grading Scales  
Acute GVHD:  
 
Consensus Clinical Stage and Grade of Acute GVHD (Glucksberg et al , 1974; Thomas et al , 1975, Przepiorka et al , 1995)  
Stage  Skin  Liver  Lower Gastrointestinal 
Tract  Upper Gastrointestinal 
Tract  
1 Maculopapular rash 
<25% of body surface  Bilirubin 2.0 – 3.0 
mg/dl  Diarrhea 500 – 1000 
mL/day or 280 – 555 
mL/m2 No protracted nausea 
and vomiting  
2 Maculopapular rash 25 -
50% body surface  Bilirubin 3.1 – 6.0 
mg/dl  Diarrhea 1000 – 1500 
mL/day or 556 – 833 
mL/m2 Persistent nausea, 
vomiting or anorexia  
3 Generalized 
erythroderma  Bilirubin 6.1 – 15.0 
mg/dl  Diarrhea >1500 mL/day or 
>833 mL/m2  
4 Generalized 
erythroderma with 
bullous formation and 
desquamation  Bilirubin > 15 mg/dl  Severe abdominal pain, 
with or without ileus, or 
stool with frank blood or 
melena   
 
 
University Of Minnesota Acute GVHD Grading  
Acute GVHD Grade Skin Stage  Liver Stage  Lower GI Stage  Upper GI Stage  
   I 1-2 0 0 0 
   II 3 1 1 1 
   III - 2-4 2-3  
   IV 4 - 4  
•  Each column identifies minimum  criteria for organ grade .  
•  Each grade is based on maximum stage for each individual organ in volved  
e.g. Grade II = skin stage 3 and/or liver stage 1 and/or gut stage 1 and/or UGI stage 1  
 
 
  